Modifying tumor-associated macrophages: An important adjunct to immunotherapy

OncoImmunology

Volumn 2, Issue 12, 2013, Pages

  Fridlender, Zvi G ^a,b   Albelda, Steven M ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

DMXAA; Immunotherapy; Lung cancer; Tumor associated macrophages; Vaccines

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; STIMULATOR OF INTERFERON GENES PROTEIN; UNCLASSIFIED DRUG; VADIMEZAN;

ADOPTIVE TRANSFER; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL TRANSFER; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; IMMUNE RESPONSE; LUNG CANCER; MACROPHAGE ACTIVATION; NATURAL KILLER T CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84896718700     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26620     Document Type: Article

References (10)

1. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012; 62:309-35; PMID:22576456; http://dx.doi.org/10.3322/ caac.20132
2. Finn OJ. Cancer immunology. N Engl J Med 2008; 358:2704-15; PMID:18565863; http://dx.doi. org/10.1056/NEJMra072739
3. Mantovani A, Germano G, Marchesi F, Locatelli M, Biswas SK. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol 2011; 41:2522-5; PMID:21952810; http:// dx.doi.org/10.1002/eji.201141894
4. Sica A, Rubino L, Mancino A, Larghi P, Porta C, Rimoldi M, Solinas G, Locati M, Allavena P, Mantovani A. Targeting tumour-associated macrophages. Expert Opin Ther Targets 2007; 11:1219-29; PMID:17845147; http://dx.doi. org/10.1517/14728222.11.9.1219
5. Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, Burdick MD, Strieter RM, Ching LM, Kaiser LR, et al. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 2005; 65:11752-61; PMID:16357188; http://dx.doi.org/10.1158/0008-5472.CAN-05-1658
6. Fridlender ZG, Jassar A, Mishalian I, Wang LC, Kapoor V, Cheng G, Sun J, Singhal S, Levy L, Albelda SM. Using macrophage activation to augment immunotherapy of established tumours. Br J Cancer 2013; 108:1288-97; PMID:23481183; http://dx.doi. org/10.1038/bjc.2013.93
7. Henare K, Wang L, Wang LC, Thomsen L, Tijono S, Chen CJ, Winkler S, Dunbar PR, Print C, Ching LM. Dissection of stromal and cancer cellderived signals in melanoma xenografts before and after treatment with DMXAA. Br J Cancer 2012; 106:1134-47; PMID:22415295; http://dx.doi. org/10.1038/bjc.2012.63
8. Lara PN Jr., Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, et al. Randomized phase III placebocontrolled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:2965-71; PMID:21709202; http://dx.doi.org/10.1200/JCO.2011.35.0660
9. Prantner D, Perkins DJ, Lai W, Williams MS, Sharma S, Fitzgerald KA, Vogel SN. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem 2012; 287:39776-88; PMID:23027866; http:// dx.doi.org/10.1074/jbc.M112.382986
10. Conlon J, Burdette DL, Sharma S, Bhat N, Thompson M, Jiang Z, Rathinam VA, Monks B, Jin T, Xiao TS, et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol 2013; 190:5216-25; PMID:23585680; http://dx.doi. org/10.4049/jimmunol.1300097